STAT3: A potential therapeutic target in dendritic cells for the induction of transplant tolerance

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 3, 2006, Pages 459-470

  Barton, Beverly E ^a  

^a University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

Allograft; IL 10; IL 6; STAT3; Tolerance; Transplantation

Indexed keywords

AUTOANTIGEN; BETA 2 MICROGLOBULIN; GLYCOPROTEIN GP 130; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; JANUS KINASE INHIBITOR; JSI 124; KYNURENINE; STAT3 PROTEIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL IMMUNITY; CELL MATURATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE EXACERBATION; DISEASE MODEL; DRUG TARGETING; EFFECTOR CELL; ENTERITIS; GLOMERULONEPHRITIS; GRAFT REJECTION; HOST RESISTANCE; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NECROTIZING COLITIS; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TOXOPLASMA GONDII; TRANSPLANTATION TOLERANCE; TUMOR IMMUNITY;

ANIMALS; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; HUMANS; IMMUNE TOLERANCE; STAT3 TRANSCRIPTION FACTOR; TISSUE TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 33745457016     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.3.459     Document Type: Review

References (110)

1. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
2. STEINMAN RM, HAWIGER D, NUSSENZWEIG MC: Tolerogenic dendritic cells. Annu. Rev. Immunol. (2003) 21:685-711.
3. ORABONA C, BELLADONNA ML, VACCA C et al.: Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol. (2005) 174(11):6582-6586.
4. MOSKOWITZ NH, BROWN DR, REINER SL: Efficient immunity against Leishmania major in the absence of interleukin-6. Infect. Immun. (1997) 65(6):2448-2450.
5. MIHARA M, IKUTA M, KOISHIRARA Y, OHSUGI Y: Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur. J. Immunol. (1991) 21:2327-2331.
6. VANHEYNINGEN TK, COLLINS HL, RUSSELL DG: IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses. J. Immunol. (1997) 158:330-337.
7. HATZIGEORGIOU DE, HE S, SOBEL J et al.: IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J. Immunol. (1993) 151(7):3682-3692.
8. NETA R, VOGEL SN, SIPE JD, WONG GG, NORDAN RP: Comparison of in vivo effects of human recombinant IL-1 and human recombinant IL-6 in mice. Lymphokine Res. (1988) 7(4):403-412.
9. PREISER JC, SCHMARTZ D, VAN DER LINDEN P et al: Interleukin-6 administration has no acute hemodynamic or hematologic effects in the dog. Cytokine (1991) 3:1-4.
10. ASANO S, OKANO A, OZAWA K et al.: In vivo effects of recombinant human IL-6 in primates: Stimulated production of platelets. Blood (1990) 75:1602-1605.
11. ADERKA D, LE J, VILCEK J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. (1989) 143(11):3517-3523.
12. ADERKA D, MAOR Y, NOVICK D et al.: Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α. Blood (1993) 81(8):2076-2084.
13. ULICH TR, GUO K, REMICK D, DEL CASTILLO J, YIN S: Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J. Immunol. (1991) 146(7):2316-2323.
14. CHEN W, HAVELL EA, GIGLIOTTI F, HARMSTEN AG: Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect. Immun. (1993) 61(1):97-102.
15. BERMUDEZ LE, WU M, PETROFSKY M, YOUNG LS: Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect. Immun. (1992) 60(10):4245-4252.
16. DENIS M: Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. J. Leuk. Biol. (1992) 52:197-201.
17. ULICH TR, YIN S, GUO K et al.: Intratracheal injection of endotoxin and cytokines II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am. J. Pathol. (1991) 138(5):1097-1101.
18. WARD NS, WAXMAN AB, HOMER RJ et al.: Interleukin-6-induced protection in hyperoxic acute lung injury. Am. J. Respir. Cell Mol. Biol. (2000) 22(5):535-542.
19. BARTON BE, JACKSON JV: The protective role of IL-6 in a septic shock model. Infect. Immun. (1993) 61(4):1496-1499.
20. BARTON BE: Effect of interleukin-6 in septic shock. Drug News Perspect. (1993) 6(9):641-646.
21. BARTON BE, SHORTALL J, JACKSON JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect. Immun. (1996) 64(3):714-718.
22. XING Z, GAULDIE J, COX G et al.: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. (1998) 101(2):311-320.
23. HEREMANS H, DILLEN C, PUT W, VAN DAMME J, BILLIAU A: Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. (1992) 22:2395-2401.
24. WANG J, HOMER RJ, CHEN Q, ELIAS JA: Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation. J. Immunol. (2000) 165(7):4051-4061.
25. CUZZOCREA S, MAZZON E, DUGO L et al.: Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice. Cytokine (2002) 18(5):274-285.
26. ATSUMI T, ISHIRARA K, KAMIMURA D et al.: A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. (2002) 196(7):979-990.
27. LEHMANN U, SCHMITZ J, WEISSENBACH M et al.: SHP2 and SOCS3 contribute to the Y759-dependent attenuation of IL-6-signaling through gpl30. J. Biol. Chem. (2003) 279(1):661-671.
28. RODRIGUEZ M, PAVELKO KD, MCKINNEY CW, LEIBOWITZ JL: Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. (1994) 153(8):3811-3821.
29. MCLOUGHLIN RM, JENKINS BJ, GRAIL D et al.: IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. USA (2005) 102(27):9589-9594.
30. QIU BS, PFEIFFER CJ, KEITH JC: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. Sci. (1996) 41(8):1625-1630.
31. DU X, LIU Q, YANG Z et al.: Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am. J. Physiol. (1997) 272(3 Pt 1):G545-G552.
32. PETERSON RL, WANG L, ALBERT L et al.: Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease. Pharmacogenomics J. (2002) 2(6):383-399.
33. VENKOVA K, KEITH JC, JR., GREENWOOD-VAN MEERVELD B: Oral treatment with recombinant human interleukin-11 improves mucosal transport in the colon of human leukocyte antigen-B27 transgenic rats. J. Pharmacol. Exp. Ther. (2004) 308(1):206-213.
34. PETERSON RL, WANG LL, ALBERT L, DORNER AJ: Subcutaneous or oral administration of rhIL-11 modulated the contact hypersensitivity response. Cytokine (2000) 12(12):1769-1777.
35. HERMANN JA, HALL MA, MAINI RN, FELDMANN M, BRENNAN FM: Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. (1998) 41(8):1388-1397.
36. WANG J, HOMER RJ, HONG L et al.: IL-11 selectively inhibits aeroallergen-induced pulmonary eosinophilia and Th2 crokine production. J. Immunol. (2000) 165(4):2222-2231.
37. SITARAMAN SV, GEWIRTZ AT: Oprelvekin. Genetics Institute. Curr. Opin. Investig. Drugs (2001) 2(10):1395-1400.
38. TRINCHIERI G, PFLANZ S, KASTELEIN RA: The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 19(5):641-644.
39. ARTIS D, VILLARINO A, SILVERMAN M et al.: The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of Type 2 immunity. J. Immunol. (2004) 173(9):5626-5634.
40. HERMANNS HM, MULLER-NEWEN G, HEINRICH PC, HAAN S: Bow to your partner for signaling. Nat. Struct. Mol. Biol. (2005) 12(6):476-478.
41. TAGA T, HIBI M, MURAKAMI M et al.: Interleukin-6 Receptors and Signals, Kishimoto T (Ed.) Kargel, Basel (1992):181-204.
42. JONES SA, RICHARDS PJ, SCHELLER J, ROSE-JOHN S: IL-6 transsignaling: the in vivo consequences. J. Interferon Cytokine Res. (2005) 25(5):241-253.
43. BOULANGER MJ, CHOW DC, BREVNOVA EE, GARCIA KC: Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp 130 complex. Science (2003) 300(5628):2101-2104.
44. SKINIOTIS G, BOULANGER MJ, GARCIA KC, WALZ T: Signaling conformations of the tall cytokine receptor gp 130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. (2005) 12(6):545-551.
45. STAHL N, BOULTON TG, FARRUGGELLA T et al.: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science (1994) 263:92-96.
46. HEINRICH PC, BEHRMANN I, MULLER-NEWEN G, SCHAPER F, GRAEVE L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. (1998) 334:297-314.
47. IMADA K, LEONARD WJ: The Jak-STAT pathway. Mol. Immunol. (2000) 37:1-11.
48. LEHMANN U, SOMMER U, SMYCZEK T et al.: Determinants governing the potency of STAT3 activation via the individual STAT3-recruiting motifs of gp130. Cell Signal. (2006) 18(1):40-49.
49. KIUCHI N, NAKAJIMA K, ICHIBA M et al.: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. (1999) 189(1):63-73.
50. O'SHEA JJ, GADINA M, SCHREIBER RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 109(Suppl.):S121-SI31.
51. GROSS M, LIU B, TAN J et al.: Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 20:3880-3887.
52. JUNICHO A, MATSUDA T, YAMAMOTO T et al.: Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem. Biophys. Res. Commun. (2000) 278:9-13.
53. JOHNSTON JA, O'SHEA JJ: Matchings SOCS with function. Nat. Immunol. (2003) 4(6):507-509.
54. LANG R, PAULEAU AL, PARGANAS E et al.: SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. (2003) 4(6):546-550.
55. ROTH W, SUSTMANN C, KIESLINGER M et al: PIASy-deficient mice display modest defects in IFN and Wnt signaling. J. Immunol. (2004) 173(10):6189-6199.
56. GERHARTZ C, HEESEL B, SASSE J et al.: Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. (1996) 271(22):12991-12998.
57. HEMMANN U, GERHARTZ C, HEESEL B et al.: Differential activation of acute phase response factor/Stat3 and Star1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. (1996) 271(22):12999-13007.
58. SEIDEL H, MILOCCO L, LAMB P et al.: Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA (1995) 92(7):3041-3045.
59. SADOWSKI HB, SHUAI K, DARNELL JE, JR., GILMAN MZ: A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science (1993) 261(5129):1739-1744.
60. ZHONG Z, WEN Z, DARNELL JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 264(5155):95-98.
61. DARNELL JE, JR.: Reflections on STAT3, STAT5, and STAT6 as fat STATs. Proc. Natl. Acad. Sci. USA (1996) 93(13):6221-6224.
62. O'GARRA A, TRINCHIERI G: Are dendritic cells afraid of commitment? Nat. Immunol. (2004) 5(12):1206-1208.
63. ABBAS AK, SHARPE AH: Dendritic cells giveth and taketh away. Nat. Immunol. (2005) 6(3):227-228.
64. PARK SJ, NAKAGAWA T, KITAMURA H et al.: IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. (2004) 173(6):3844-3854.
65. KITAMURA H, KAMON H, SAWA SI et al.: IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity (2005) 23(5):491-502.
66. HOENTJEN F, SARTOR RB, OZAKI M, JOBIN C: STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood (2005) 105(2):689-696.
67. MELLOR AL, MUNN DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. (2004) 4(10):762-774.
68. BABAN B, HANSEN AM, CHANDLER PR et al: A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via Type I IFN signaling following B7 ligation. Int. Immunol. (2005) 17(7):909-919.
69. MUNN DH, SHARMA MD, LEE JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 297(5588):1867-1870.
70. MUNN DH, SHARMA MD, HOU D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. (2004) 114(2):280-290.
71. FALLARINO F, GROHMANN U, HWANG KW et al.: Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. (2003) 4(12):1206-1212.
72. FALLARINO F, VACCA C, ORABONA C et al.: Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int. Immunol. (2002) 14(1):65-68.
73. MELLOR AL, BABAN B, CHANDLER PR et al: Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. (2005) 175(9):5601-5605.
74. GROHMANN U, FALLARINO F, BIANCHI R et al.: A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. (2003) 198(1):153-160.
75. LEE GK, PARK HJ, MACLEOD M et al.: Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology (2002) 107(4).452-460.
76. FALLARINO F, GROHMANN U, VACCA C et al.: T cell apoptosis by tryptophan catabolism. Cell Death Differ. (2002) 9(10):1069-1077.
77. FALLARINO F, GROHMANN U, VACCA C et al.: T cell apoptosis by kynurenines. Adv. Exp. Med. Biol. (2003) 527:183-190.
78. CHENG F, WANG HW, CUENCA A et al.: A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 19(3):425-436.
79. NEFEDOVA Y, HUANG M, KUSMARTSEV S et al.: Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. (2004) 172(1):464-474.
80. NEFEDOVA Y, NAGARAJ S, ROSENBAUER A et al.: Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/ signal transducers and activators of transcription 3 pathway. Cancer Res. (2005) 65(20):9525-9535.
81. KORTYLEWSKI M, KUJAWSKI M, WANG T et al.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. (2005) 11(12):1314-1321.
82. YOO J-Y, HUSO DL, NATHANS D, DESIDERIO S: Specific ablation of STAT3β distorts the pattern of STAT3-responsive gene expression and impairs recovery from endotoxic shock. Cell (2002) 108:331-344.
83. BEAMAN MH, HUNTER CA, REMINGTON JS: Enhancement of intracellular replication of Taxoplasma gondii by IL-6. J. Immunol. (1994) 153:4583-4587.
84. CORINTI S, ALBANESI C, LA SALA A, PASTORE S, GIROLOMONI G: Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. (2001) 166(7):4312-4318.
85. KOBAYASHI M, KWEON MN, KUWATA H et al.: Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in mycloid cell-specific Stat3-deficient mice. J. Clin. Invest. (2003) 111(9):1297-1308.
86. LANG R: Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology (2005) 210(2-4):63-76.
87. HOLSCHER C, HOLSCHER A, RUCKERL D et al.: The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. (2005) 174(6):3534-3544.
88. SUN J, WALSH M, VILLARINO AV et al.: TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development. J. Immunol. (2005) 174(2):742-751.
89. HAMANO S, HIMENO K, MIYAZAKI Y et al.: WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity (2003) 19(5):657-667.
90. YOSHIDA H, HAMANO S, SENALDI G et al.: WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity (2001) 15(4):569-578.
91. TAKEDA A, HAMANO S, SHIRAISHI H et al.: WSX-1 over-expression in CD4(+) T cells leads to hyperproliferation and cytokine hyperproduction in response to TCR stimulation. Int. Immunol. (2005) 17(7):889-897.
92. HUNTER CA, VILLARINO A, ARTIS D, SCOTT P: The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol. Rev. (2004) 202:106-114.
93. PETERSON RL, WANG L, ALBERT L, KEITH JC, DORNER AJ: Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab. Invest. (1998) 78(12):1503-1512.
94. MIYAZAKI Y, INOUE H, MATSUMURA M et al.: Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J. Immunol. (2005) 175(4):2401-2407.
95. H2-type immune deviations in MRL/1pr mice deficient for IL-27 receptor (WSX-1). J. Immunol. (2005) 175(11):7185-7192.
96. KAWAKAMI Y, INAGAKI N, SALEK-ARDAKANI S et al.: Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc. Natl. Acad. Sci. USA (2006) 103(1):153-158.
97. WELTE T, ZHANG SS, WANG T et al.: STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Nad. Acad. Sci. USA (2003) 100(4):1879-1884.
98. METCALFE SM, WATSON TJ, SHUREY S, ADAMS E, GREEN CJ: Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation (2005) 79(6):726-730.
99. NEFEDOVA Y, CHENG P, GILKES D et al.: Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. (2005) 175(7):4338-4346.
100. XIE J, WANG Y, FREEMAN ME 3rd, BARLOGIE B, YI Q. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood (2003) 101(10):4005-4012.
101. BARTON BE, FINKELMAN FD: Anti-inflammatory cytokines. Agents Actions (1993) 39:R1-R3.
102. NAITOH Y, FUKATA J, TOMINAGA T et al.: Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats Biochem. Biophys. Res. Comm. (1988) 155:1459-1463.
103. BOELEN A, MAAS MA, LOWIK CW, PLATVOET MC, WIERSINGA WM: Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3′-triiodothyronine syndrome. Endocrinol. (1996) 137(12):5250-5254.
104. DENG C, GOLUSZKO E, TUZUN E, YANG H, CHRISTADOSS P: Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. (2002) 169:1077-1083.
105. SAMILOVA EB, HORTON JL, HILLIARD B, LIU T-ST, CHEN Y: IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoimmune T cells. J. Immunol. (1998) 161:6480-6486.
106. HO LJ, HUNG LF, WENG CY et al.: Dengue virus type 2 antagonizes IFN-{alpha} but not IFN-{gamma} antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J. Immunol. (2005) 174(12):8163-8172.
107. LAOUAR Y, WELTE T, FU XY, FLAVELL RA: STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity (2003) 19(6):903-912.
108. RATHINAM C, GEFFERS R, YUCEL R et al.: The transcriptional repressor Gfi1 controls STAT3-dependent dendritic cell development and function. Immunity (2005) 22(6):717-728.
109. + T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. (2005) 175(3):1686-1693.
110. BARTON BE: Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin. Ther. Targets (2005) 9(4):737-752.